For the treatment of mild to moderate hypertension.
For prevention of cardiovascular morbidity and mortality in patients, 55 years older at high risk of cardiovascular disease.
Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in tissues, such as vascular smooth muscle and the adrenal gland. Telmisartan has much greater affinity for the AT1 receptor than for the AT2 receptor.
In hypertension the usual starting dose of Telmisartan is 40 mg once a day. Blood pressure response is dose-related over the range of 20 to 80mg. For cardiovascular risk reduction, the recommended dose is 80 mg per day administered with or without food.
Known hypersensitivity (e.g., anaphylaxis or angioedema) to telmisartan or any other component of this product.
Fetal/Neonatal morbidity and mortality, hyperkalemia,symptomatic hypotension, impaired hepatic and renal function.
Pregnancy Categories C (first trimester) and D (second and third trimesters). Discontinue telmisartanas soon as possiblewhen pregnancy is detected.Choose to discontinue nursing or drug, during lactation. Safety and effectiveness in pediatric patients have not been established.
Telmisartan increases levelof digoxin and Lithium. Deterioration of renal function, including possible acute renal failure may occur if telmisartan is co-administered with NSAIDs including selective COX-2 inhibitors.
The most common adverse events areback pain, sinusitis, and diarrhea.